Exchange: OTC·Updated 07:30 PM EST
PPCB logo

PPCB Propanc Biopharma Inc

$1.73
$0.055
(3.19%)
Today
Closed $1.78
$0.05
(2.81%)
After Hours
Mkt Cap$1.84M
Vol27,874.00

About PPCB

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.
54

Neutral Sentiment

How do you feel about PPCB?

TwongStocks
Tracking a total of 13(!!!) reverse splits on Monday - 11 on NASDAQ and 2 on the NYSE American. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am Monday morning. Will have to split this summary into 3 parts. Part 3 of 3: $PPCB 1 for 10. Will reduce outstanding shares from approx 10.33m to approx 1.03m. $SBFM 1 for 20. Will reduce outstanding shares from approx 15.22m to approx 1.52m. $SXTC 1 for 100. Will reduce outstanding Class A shares from approx 68.68m to approx 687k. $TWG 1 for 100. Will reduce outstanding Class A shares from approx 59.58m to approx 596k.
1
4
strong_Dan
$PPCB Yo, be respectful with the stock, quote the full history! 1.8 quintillion to one in reverse splits, that's 10 with 18 zeroes :D This should be a lesson to all of us when we spark that thing in the head "maybe it won't crash/how low can it go" -- I'm out of it for a big loss and now short it sporadically (for guaranteed greens). CJMB also caught me recently , same institution ex_crement Hextone.
1
TradeUp222
$PPCB thats how they do it, when everyone gets sick and tired of it and takes it off watch list, they cover
1
URANIUM77
$PPCB Propanc Biopharma ($PPCB) results show 90% inhibition of tumor growth. FDA Orphan Drug Designation for pancreatic cancer—and more is on the way. An amazing journey lies ahead.
2
ReversalRuler
If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ $PPCB $LHSW $IPW $HKPD ✓
2
URANIUM77
$PPCB This company is extremely undervalued and will reach a valuation in the billions within a year. They have a fantastic product for cancer treatment under development. 90% tumor [reduction/effect]
2
URANIUM77
$PPCB $PPCB 🧬💥 Read this carefully: PRP is NOT trying to replace chemotherapy. PRP appears to make chemotherapy work AGAIN. Let that sink in. Cancer cells that learned how to survive treatment were reportedly reprogrammed and made vulnerable once more. That's potentially a MASSIVE breakthrough mechanism. ✅ Reduced proliferation ✅ Reduced invasion ✅ Reversed aggressive cancer traits ✅ Restored therapeutic vulnerability Wall Street sleeps on microcaps until the data becomes impossible to ignore. PPCB market cap = tiny. Addressable market = enormous. If clinical results confirm the science, this could be one of those stocks people wish they bought before the crowd noticed. Not financial advice. Just connecting the dots. 👀🚀🚀🚀 #PPCB
2
strong_Dan
$PPCB I've got an idea since this Hexstone also drilled to the ground CJMB this week, same, shameless sell no matter time or price ..... .. not wait even to pay the reverse split fee on my broker.. just dump what's left..... .... and start a shorting rampage Monday, rotate like a MM, commissions free, in-out on keyboard. This stock never held high. There is the 6.5M Hexstone on top of the 10M (adjusted Monday to 1.65M). They never held a high even one day, red closing after any spike (if any to be expected). Yea, somehow I know they won't be hurt, they did splits in total of quadrillion to one, that's 10 followed by 15 zeroes. Though it's opportunity, why getting trapped on the low when on short it's guaranteed it won't hold much the pain? ..if you averaged at.. let's say $1 ... now Monday you want to break even at $10 . It has no chance to go there. Orr, as a trader, if it goes just jump on the signal, never hope just observe. Good luck! I mean, good attention! :)
2
IR_propancbiopharma
From preclinical research to clinical development preparations, several milestones have helped shape $PPCB's path forward in 2026. · Q1: Preclinical findings, research collaborations, and bioanalytical development. · Q2: GMP manufacturing preparations to support clinical development. · Q3: Clinical protocol development, site feasibility assessments, and a clearer Phase 1b roadmap. · Q4: Additional preclinical findings, analytical progress, and preparations for regulatory and ethics submissions. What's next? Propanc is targeting a Phase 1b first-in-human study involving up to 50 patients with advanced solid tumors, with initial patient screening planned for February 2027. The next milestone is translating these preparations into clinical execution.
1
MrTicker
$PPCB Propanc Biopharma Announces New Preclinical Data Supporting Potential Of PRP To Treat Chemotherapy Resistance In Pancreatic Cancer; PRP Monotherapy Reduced Cancer Cell Proliferation By ~50–54% And Suppressed Long-term Clonogenic Survival By Up To 59% BENZINGA 7:32 AM ET 10/26/2026
1
Stock_Catcher
$PPCB Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
1
IR_propancbiopharma
Progress isn't linear. Especially in clinical development. For $PPCB, Nasdaq compliance is one challenge. Securing the capital needed to advance PRP toward its planned Phase 1b first-in-human trial in Q1 2027 is another. Access to capital is essential to support several critical steps: • Advancing GMP manufacturing preparations for PRP. • Completing regulatory and ethics approval processes. • Preparing clinical trial sites for patient enrollment. The reverse split addresses a listing requirement. Capital supports the work needed to reach the clinic. And each completed milestone brings PRP closer to its next objective: evaluation in up to 50 patients with advanced solid tumors. $PPCB
1
IR_propancbiopharma
Not every step forward makes headlines. Some of the most important work happens behind the scenes. As $PPCB navigates a period of corporate adjustments, its latest preclinical findings showed PRP reduced the proliferation of chemotherapy-resistant pancreatic cancer cells by approximately 50–54%. Now the focus is on advancing PRP toward clinical evaluation. Preparations include GMP manufacturing, pharmacokinetic assay validation, regulatory and ethics processes, and clinical site readiness. With a Phase 1b first-in-human study planned for Q1 2027, the next chapter will depend on execution. The work now is about turning scientific evidence into clinical progress. $PPCB
MrTicker
$PPCB Propanc Biopharma Says PRP Cut Pancreatic Cancer Cell Proliferation By About 50% In Preclinical Study; Files Australian Patent Application On Galunisertib Combination BENZINGA 7:32 AM ET 11/2/2026
Golibajje
$PPCB i called out this one! Unlimited reverse splits and offerings.. and finally will get thrown out to OTC! This is exactly like $TCBP
Rexracer13
$PPCB lol. ANOTHER REVERSE SPLIT. SEC NEEDS TO HALT TRADING OF THIS STOCK. REMOVE IT FOREVER.
focafoca99
$PPCB notified Nasdaq of a delisting notice for failing the $1.00 bid price, with appeal planned by Oct 30.
Golibajje
$PPCB Look at the balance sheet. cash is under $1M!! Another $TCBP with unlimited offerings and reverse splits.. finally would be thrown to OTC!
Golibajje
$PPCB As a retail shareholder, why would i buy a stock which has only gone down, continuously going down, risk of frequent dilution, etc.
MrTicker
$PPCB Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer PatientsHuman Research Ethics Submission Deadline Nov ‘26 with Site Initiation Activities Followed by First Patient Screening Planned for Feb ‘27 GLOBENEWSWIRE 7:30 AM ET 10/28/2026

Advertisement|Remove ads.